B. Metzler seel. Sohn & Co. AG Sells 211 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

B. Metzler seel. Sohn & Co. AG decreased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 42,132 shares of the medical equipment provider’s stock after selling 211 shares during the period. B. Metzler seel. Sohn & Co. AG’s holdings in Zimmer Biomet were worth $4,450,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the company. Stonebridge Financial Group LLC acquired a new stake in shares of Zimmer Biomet in the 4th quarter valued at $25,000. Dunhill Financial LLC boosted its stake in Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 218 shares in the last quarter. Kentucky Trust Co bought a new position in Zimmer Biomet in the fourth quarter valued at about $39,000. OFI Invest Asset Management acquired a new position in Zimmer Biomet during the fourth quarter worth about $40,000. Finally, SRS Capital Advisors Inc. lifted its holdings in shares of Zimmer Biomet by 146.9% in the fourth quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider’s stock worth $51,000 after acquiring an additional 285 shares during the last quarter. 88.89% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ZBH has been the subject of a number of research analyst reports. Barclays lowered their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday, February 10th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. JMP Securities restated a “market outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 7th. Truist Financial reiterated a “hold” rating and issued a $113.00 target price (down from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Finally, Raymond James reduced their price target on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and an average target price of $124.15.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. This represents a 14.13 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.95% of the company’s stock.

Zimmer Biomet Stock Up 1.0 %

Shares of NYSE:ZBH opened at $113.33 on Tuesday. The business’s 50-day moving average is $107.26 and its 200-day moving average is $107.10. Zimmer Biomet Holdings, Inc. has a 1 year low of $97.69 and a 1 year high of $131.61. The company has a market capitalization of $22.56 billion, a price-to-earnings ratio of 25.47, a P/E/G ratio of 1.95 and a beta of 1.04. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the business posted $2.20 EPS. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 0.85%. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.